Axsome Therapeutics Stock Forecast NASDAQ:AXSM

Price Target and Analyst Ratings

Most Recent Rating

On September 15, 2021 "HC Wainwright" gave "$180.00" rating for AXSM. The price target was set to $28.38+8.4%.

Last 30 Days

Historical Ratings

Date	Rating	Action	Authority	Current Price	Target Price
2021-09-15	$180.00	Reiterated by	HC Wainwright	$27.72	$28.38+8.4%
2021-08-30	$225.00 - $180.00	Reiterated by	HC Wainwright	$24.38	$24.00+3.2%
2021-08-30	$225.00 - $180.00	Target Lowered by	HC Wainwright	$24.38	$24.25+1.0%
2021-08-27		Reiterated by	William Blair	$24.00	$24.02+3.3%
2021-08-23	$55.00	Reiterated by	Mizuho	$24.79	$22.89+6.2%
2021-08-10	$200.00 - $160.00	Target Lowered by	Truist Securities	$23.78	$24.04→12.2%
2021-08-10	$118.00 - $55.00	Target Lowered by	Mizuho	$23.78	$27.37→46.5%
2021-08-10	$105.00 - $34.00	Downgraded by	Morgan Stanley	$23.78	$27.37→46.5%
2021-08-10	$200.00 - $160.00	Target Lowered by	Truist	$23.78	$23.70→13.4%
2021-08-10	$115.00 - $75.00	Target Lowered by	SVB Leerink	$23.78	$23.70→13.4%
2021-08-10	$123.00 - $55.00	Target Lowered by	BTIG Research	$23.78	$23.42→14.4%
2021-07-16	$56.77	Target Set by	William Blair	$54.22	$55.02→3.1%
2021-07-16		Reiterated by	William Blair	$54.22	$56.77→0.1%
2021-06-10	Buy	Initiated by	Berenberg Bank	$67.57	$112.00
2021-05-26	Overweight	Target Raised by	Morgan Stanley	$56.23	$104.00 → $105.00
2021-05-12	Buy	Reiterated by	BTIG Research	$57.01
2021-05-03	Buy	Target Raised by	HC Wainwright	$61.55	$210.00 → $225.00
2021-04-27	Buy	Target Raised by	HC Wainwright	$60.39	$210.00 → $225.00
2021-04-27	Buy	Reiterated by	HC Wainwright	$60.39	$210.00 → $225.00
2021-03-08	Overweight	Target Raised by	Morgan Stanley	$62.82	$101.00 → $104.00
2021-03-02	Overweight	Target Raised by	Morgan Stanley	$69.76	$101.00 → $104.00
2021-03-02	Buy	Target Lowered by	Mizuho	$69.76	$120.00 → $118.00
2021-01-08	Buy	Initiated by	Jefferies Financial Group	$77.71	$129.00
2020-12-31	Positive	Reiterated by	UBS Group	$81.47
2020-12-15	Buy	Initiated by	Mizuho	$80.05	$120.00
2020-12-15	Buy	Initiated by	Mizuho	$80.05
2020-12-03	Positive - Overweight	Target Raised by	Cantor Fitzgerald	$77.15	$131.00 → $161.00
2020-11-09	Overweight	Target Lowered by	Morgan Stanley	$68.82	$102.00 → $101.00
2020-10-01	Buy	Reiterated by	William Blair	$72.21
2020-09-29	Underperform	Initiated by	BofA Securities	$72.28	$66.00
2020-09-29	Underperform	Initiated by	Bank of America	$72.28	$66.00
2020-09-10	Overweight	Initiated by	Morgan Stanley	$73.03	$102.00
2020-08-21	Buy	Reiterated by	William Blair	$77.57
2020-08-10	Buy	Reiterated by	William Blair	$81.79
2020-08-06	Buy	Reiterated by	HC Wainwright	$78.04	$210.00
2020-07-14	Buy	Reiterated by	HC Wainwright	$79.42	$210.00
2020-06-30	Buy	Reiterated by	HC Wainwright	$82.28	$210.00
2020-04-28	Buy	Target Raised by	HC Wainwright	$96.35	$200.00 → $210.00
2020-04-28	In-Line - Buy	Target Raised by	Guggenheim	$96.35	$158.00 → $200.00
2020-04-27	Positive - Buy	Target Raised by	SunTrust Banks	$95.00	$145.00 → $200.00
2020-04-27	Overweight	Target Raised by	Cantor Fitzgerald	$95.00	$125.00 → $131.00
2020-04-27	Positive - Buy	Target Raised by	LADENBURG THALM/SH SH	$95.00	$165.00 → $186.00
2020-04-14	Outperform	Initiated by	Cowen	$65.91	$95.00

AXSM Stock Trend

Given the current short-term trend, the stock is expected to fall -67.30% during the next 3 months and, with a 90% probability hold a price between $0.72 and $9.33 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.

Data

Date	Bottom	Mid	Top
2021-09-20	$1.27	$14.43	$27.60
2021-09-21	$0.34	$13.50	$26.67
2021-09-22	$-0.60	$12.57	$25.73
2021-09-23	$-1.53	$11.64	$24.80
2021-09-24	$-2.46	$10.70	$23.87
2021-09-27	$-3.39	$9.77	$22.94
2021-09-28	$-4.32	$8.84	$22.01
2021-09-29	$-5.26	$7.91	$21.07
2021-09-30	$-6.19	$6.98	$20.14
2021-10-01	$-7.12	$6.04	$19.21
2021-10-04	$-8.05	$5.11	$18.28
2021-10-05	$-8.99	$4.18	$17.34
2021-10-06	$-9.92	$3.25	$16.41
2021-10-07	$-10.85	$2.32	$15.48
2021-10-08	$-11.78	$1.38	$14.55
2021-10-11	$-12.71	$0.45	$13.62
2021-10-12	$-13.65	$-0.48	$12.68
2021-10-13	$-14.58	$-1.41	$11.75
2021-10-14	$-15.51	$-2.35	$10.82
2021-10-15	$-16.44	$-3.28	$9.89
2021-10-18	$-17.37	$-4.21	$8.96
2021-10-19	$-18.31	$-5.14	$8.02
2021-10-20	$-19.24	$-6.07	$7.09
2021-10-21	$-20.17	$-7.01	$6.16
2021-10-22	$-21.10	$-7.94	$5.23
2021-10-25	$-22.03	$-8.87	$4.30
2021-10-26	$-22.97	$-9.80	$3.36
2021-10-27	$-23.90	$-10.73	$2.43
2021-10-28	$-24.83	$-11.67	$1.50
2021-10-29	$-25.76	$-12.60	$0.57

About Axsome Therapeutics

Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, develops therapies for the management and treatment of central nervous system disorders. Its product candidates include AXS-02, which is in Phase III trial for the treatment of complex regional pain syndrome, knee osteoarthritis, and chronic low back pain; and AXS-05 that is in Phase III trial for the treatment of resistant depression and agitation in patients with Alzheimer's... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!